Interestingly, in this context, the binding of ERα by estrogens or the absence of hormone stimulation showed different contributions to BC progression and cancer cell survival, suggesting a new landscape that might be studied and exploited for novel potential therapeutic target identification. The gene discussed is ESR1; the disease is cancer.